Search

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.worlddev.2005.07.010 Byline: Joanna Chataway Keywords: HIV/AIDS; public-private partnerships; advocacy; capacity building; Africa; India Abstract: Product based public-private partnerships (PPPs), of which the International Aids Vaccine Initiative (IAVI) is one, are being developed to try and bridge the gap between scientific and technological potential and the needs of developing countries. First, this paper examines PPP's popularity. Second, we describe key characteristics of IAVI and explain why it differs from more traditional partnerships. Third, IAVI has had some success in bringing new science and technology closer to the world's poor and we look at how it has achieved this success and implications for theoretical and practical approaches to science and technology capacity building. Author Affiliation: ESRC INNOGEN Research Centre, The Open University, UK Article History: Accepted 25 July 2005

Between 1970 and 2000, the proportion of global R&D occurring in low-income economies rose from 2 per cent to more than 20 per cent. However, this rising commitment to R&D does not easily translate into the emergence of a family of innovations meeting the needs of low-income consumers ‘at the bottom of the pyramid’, since much of these technological resources are invested in outdated structures of innovation. A number of transnational corporations are targeting these markets, but it is our contention that much of the previously dominant innovation value chains are either ignorant of the needs of consumers at the bottom of the pyramid or lack the technologies and organizational structures to meet these needs effectively. Instead, the firms and value chains which are likely to be most successful in these dynamic new markets are those which are emerging in China and India and other developing countries, disrupting global corporate and locational hierarchies of innovation. [ABSTRACT FROM AUTHOR]

Some industrially advanced developing countries have, in the last decades, built substantial pharmaceutical scientific and industrial capabilities. The more advanced of these countries have built chemical and biological R&D, generic and reverse engineering, and drug discovery capabilities. There have been tremendous barriers to entry but nevertheless a range of imitative approaches have evolved, with some significant scientific, health and industrial advances. Opportunities in India are in part created by the problems of maturity being faced by big pharmaceutical firms in developed countries. Big pharmaceutical firms are searching for novel approaches to retain a high value-added model of innovation for drug development. These difficulties provide opportunities for innovative companies in developing countries. This paper explores the challenges faced under these circumstances by Indian pharmaceutical companies. Are they attempting to 'catch-up' by chasing a failing model of innovation? Do they have an alternative model? Or can they become an important part of a transformed new global model of pharmaceutical innovation? [ABSTRACT FROM AUTHOR]